MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Study Investigates Survival Rates of Bladder Cancer Patients

By MedImaging International staff writers
Posted on 06 Jun 2017
Print article
A large-scale study of cancer patients has revealed that was no difference between the survival rates following radical bladder removal surgery compared to bladder-preserving combined modality treatment.

The researchers looked at data from 19 previously published cancer research papers including 12,380 patients with Muscle-Invasive Bladder Cancer (MIBC).

The research was published in the April 1, 2017, issue of the International Journal of Radiation Oncology*Biology*Physics, of the American Society for Radiation Oncology by researchers from the University of Texas Health Science Center (UT Health San Antonio; San Antonio, TX, USA).

The researchers compared overall 10-year survival, progression-free survival, disease-specific survival, complications as a result of radical cystectomy treatment, and Combined Modality Treatment (CMT) that consisted of Radiation Therapy (RT), chemotherapy, and transurethral resection of the tumor.

The researchers concluded that CMT could be considered as a standard first approach for patients with muscle-invasive bladder cancer (MIBC) instead of the current standard of Radical Cystectomy (RC), which necessitates additional surgery to construct a new urine storage system for the patient.

Senior author of the study, assistant professor Dharam Kaushik, MD, UT Health San Antonio, said, "These results provide compelling evidence suggesting radiation therapy may be as good as surgery for many of these patients. We hope this study will help patients and their physicians understand the full range of options available when planning treatment for muscle-invasive bladder cancer. According to our analyses, patients undergoing radical cystectomy likely share no cancer survival benefits compared with patients receiving chemoradiation-based bladder preservation therapy. Further research is needed to evaluate these two treatment arms – radical cystectomy versus combined modality treatment – to identify optimal treatments for specific patients."

Related Links
University of Texas Health Science Center

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Compact C-Arm
Arcovis DRF-C S21
Computed Tomography (CT) Scanner
Aquilion Serve SP
Silver Member
Mobile X-Ray Barrier
Lead Acrylic Mobile X-Ray Barriers

Print article

Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more